Weekly docetaxel and mitoxantrone prior to prostatectomy in patients with high risk localized prostate cancer

被引：0
|
作者：
Beer, TM
Garzotto, M
Lowe, BA
Ellis, WJ
Lange, PH
Montalto, MA
Higano, C
机构：
来源：
JOURNAL OF UROLOGY | 2003年 / 169卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
1662
引用
收藏
页码：444 / 444
页数：1
相关论文
共 50 条
  • [31] Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy.
    Friedlander, Terence W.
    Anantharaman, Archana
    Welty, Christopher
    Zejnullahu, Kreshnik
    Hough, Jeffrey
    Edwards, Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [32] Docetaxel weekly for advanced prostate cancer
    Pepe, A.
    Usset, A.
    Savio, G.
    Leonardi, V.
    Calabria, C.
    Palmisano, V.
    Grassadonia, A.
    Laudani, A.
    Alu, M.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2005, 16 : 155 - 155
  • [33] Neoadjuvant docetaxel and estramustine followed by radical prostatectomy or radiation therapy for patients with high-risk prostate cancer
    Stefaniak, H
    Wallen, E
    Baggstrom, M
    Godley, P
    Rosenman, J
    Goyal, L
    Whang, Y
    Pruthi, RS
    JOURNAL OF UROLOGY, 2005, 173 (04): : 190 - 190
  • [34] SURGICAL OUTCOMES OF NEOADJUVANT DOCETAXEL CHEMOTHERAPY COMPARED WITH RADICAL PROSTATECTOMY ALONE IN PATIENTS WITH HIGH RISK PROSTATE CANCER
    Kang, Taejin
    Kim, Wansuk
    Lee, Jungmin
    Song, Cheryn
    Kim, Jun Hyuk Hong Choung-Soo
    Seoul, Ahn
    JOURNAL OF UROLOGY, 2010, 183 (04): : E230 - E230
  • [35] Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer
    Friedman, Judah
    Dunn, Rodney L.
    Wood, David
    Vaishampayan, Ulka
    Wu, Angela
    Bradley, Deborah
    Montie, James
    Sarkar, Fazlul H.
    Shah, Rajal B.
    Hussain, Maha
    JOURNAL OF UROLOGY, 2008, 179 (03): : 911 - 915
  • [36] Rationale for and Review of Neoadjuvant Therapy Prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer
    Rana R. McKay
    Toni K. Choueiri
    Mary-Ellen Taplin
    Drugs, 2013, 73 : 1417 - 1430
  • [37] Rationale for and Review of Neoadjuvant Therapy Prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer
    McKay, Rana R.
    Choueiri, Toni K.
    Taplin, Mary-Ellen
    DRUGS, 2013, 73 (13) : 1417 - 1430
  • [38] The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy
    Lokeshwar, Soum D.
    Ali, Ather
    Weiss, Theresa R.
    Reynolds, Jesse
    Shuch, Brian M.
    Ferencz, Thomas
    Kyriakides, Tassos C.
    Mehal, Wajahat Z.
    Brito, Joseph
    Renzulli, Joseph
    Leapman, Michael S.
    BMC UROLOGY, 2024, 24 (01):
  • [39] Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates
    Bergstrom, Colin P.
    Ruffell, Brian
    Ho, Christine M. T.
    Higano, Celestia S.
    Ellis, William J.
    Garzotto, Mark
    Beer, Tomasz M.
    Graff, Julie N.
    ANTI-CANCER DRUGS, 2017, 28 (01) : 120 - 126
  • [40] Safety and Efficacy of Neoadjuvant Docetaxel and Radiotherapy in Localized High-Risk Prostate Cancer
    Ohaegbulam, Kim C.
    Post, Carl M.
    Farris, Paige E.
    Garzotto, Mark
    Beer, Tomasz M.
    Hung, Arthur
    Williamson, Casey W.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (02): : 75 - 82
12345